Sanofi (NASDAQ:SNY) Stock Rating Raised to Buy at Wall Street Zen

Posted by Geri Gentry on Nov 8th, 2026

Wall Street Zen upgraded shares of Sanofi (NASDAQ:SNY – Free Report) from a hold rating to a buy rating in a report issued on Saturday morning,Wall Street Zen reports.

Several other equities analysts have also recently issued reports on the company. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research note on Thursday, October 1st. Weiss Ratings upgraded shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, November 2nd. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a report on Thursday, September 17th. HSBC reiterated a “buy” rating on shares of Sanofi in a research note on Thursday, September 10th. Finally, DZ Bank reiterated a “buy” rating on shares of Sanofi in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and thirteen have assigned a Hold rating to the stock. Based on data from MarketBeat, Sanofi currently has an average rating of “Hold” and a consensus target price of $49.50.

Get Our Latest Stock Analysis on SNY

Sanofi Stock Up 0.3%

Shares of NASDAQ SNY opened at $47.04 on Friday. The stock has a market cap of $114.05 billion, a P/E ratio of 23.29, a PEG ratio of 1.29 and a beta of 0.31. The company has a current ratio of 1.12, a quick ratio of 0.64 and a debt-to-equity ratio of 0.20. Sanofi has a 12-month low of $39.07 and a 12-month high of $52.68. The business’s fifty day simple moving average is $42.30 and its 200-day simple moving average is $44.34.

Sanofi (NASDAQ:SNY – Get Free Report) last released its earnings results on Friday, October 30th. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.56 by $0.48. Sanofi had a return on equity of 15.16% and a net margin of 8.70%. The firm had revenue of $17.25 billion during the quarter, compared to analyst estimates of $14.30 billion. During the same period last year, the business posted $2.91 earnings per share. Sanofi’s revenue was up 16.2% compared to the same quarter last year. As a group, equities analysts predict that Sanofi will post 5.06 EPS for the current fiscal year.

Institutional Investors Weigh In On Sanofi

Several institutional investors have recently added to or reduced their stakes in SNY. Root Financial Partners LLC purchased a new position in Sanofi in the third quarter valued at approximately $27,000. Western Wealth Management LLC acquired a new stake in Sanofi during the first quarter worth approximately $29,000. Signature Equity Partners LLC lifted its position in shares of Sanofi by 322.2% during the 3rd quarter. Signature Equity Partners LLC now owns 857 shares of the company’s stock worth $35,000 after buying an additional 654 shares during the last quarter. Whipplewood Advisors LLC lifted its position in shares of Sanofi by 2,086.1% during the 1st quarter. Whipplewood Advisors LLC now owns 787 shares of the company’s stock worth $38,000 after buying an additional 751 shares during the last quarter. Finally, Financial Network Wealth Advisors LLC lifted its position in shares of Sanofi by 103.3% during the 3rd quarter. Financial Network Wealth Advisors LLC now owns 911 shares of the company’s stock worth $38,000 after buying an additional 463 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Company Profile

(Get Free Report)

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world.

Sanofi traces its origins to a company established in France in 1973.